AR076407A1 - Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo. - Google Patents

Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.

Info

Publication number
AR076407A1
AR076407A1 ARP100101374A ARP100101374A AR076407A1 AR 076407 A1 AR076407 A1 AR 076407A1 AR P100101374 A ARP100101374 A AR P100101374A AR P100101374 A ARP100101374 A AR P100101374A AR 076407 A1 AR076407 A1 AR 076407A1
Authority
AR
Argentina
Prior art keywords
chloro
formula
fluoroanilino
quinazoline
piperidin
Prior art date
Application number
ARP100101374A
Other languages
English (en)
Inventor
Kay Alison Boardman
Oliver Robert Cunningham
David Dermot Patrick Laffan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR076407A1 publication Critical patent/AR076407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Procesos para preparar 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(N-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina y sales de esta, e intermediarios usados en el proceso. Reivindicacion 1: Un proceso para preparar 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(N-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina o una sal de ésta, caracterizado porque comprende (a) hacer reaccionar un compuesto de formula (2) con 3-cloro-2-fluoroanilina, en presencia de un ácido apropiado; o (b) hacer reaccionar un compuesto de formula (3)con un compuesto de formula (9) o de formula (12) en presencia de un ácido apropiado. Reivindicacion 9: Un compuesto, caracterizado porque es de formula (13) o una sal del mismo donde R1 es H, -NH2, -NO2, -N=C-N(CH3)2; R2 es H, N-metilcarbamoilmetilo, o Pg1, y Pg1 es un grupo protector de amino; con la condicion de que cuando R2 es H o un grupo protector de amino entonces R1 es H. Reivindicacion 12: Un compuesto, caracterizado porque es de formula (11), formula (12) o una sal del mismo.
ARP100101374A 2009-04-23 2010-04-23 Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo. AR076407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
AR076407A1 true AR076407A1 (es) 2011-06-08

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101374A AR076407A1 (es) 2009-04-23 2010-04-23 Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.

Country Status (14)

Country Link
US (1) US8450482B2 (es)
EP (1) EP2421827A2 (es)
JP (1) JP2012524769A (es)
KR (1) KR20120007059A (es)
CN (1) CN102459174A (es)
AR (1) AR076407A1 (es)
AU (1) AU2010240717A1 (es)
BR (1) BRPI1013854A2 (es)
CA (1) CA2758610A1 (es)
IL (1) IL215388A0 (es)
MX (1) MX2011011177A (es)
SG (1) SG174893A1 (es)
TW (1) TW201041871A (es)
WO (1) WO2010122340A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
SI1667992T1 (sl) * 2003-09-19 2007-06-30 Astrazeneca Ab Kinazolinski derivati
US20070299092A1 (en) * 2004-05-20 2007-12-27 Wyeth Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
WO2009138779A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
JP5739802B2 (ja) * 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩

Also Published As

Publication number Publication date
WO2010122340A3 (en) 2011-09-09
TW201041871A (en) 2010-12-01
MX2011011177A (es) 2011-11-18
IL215388A0 (en) 2011-12-29
WO2010122340A8 (en) 2011-12-15
US8450482B2 (en) 2013-05-28
KR20120007059A (ko) 2012-01-19
WO2010122340A2 (en) 2010-10-28
EP2421827A2 (en) 2012-02-29
US20120108814A1 (en) 2012-05-03
CN102459174A (zh) 2012-05-16
SG174893A1 (en) 2011-11-28
CA2758610A1 (en) 2010-10-28
AU2010240717A1 (en) 2011-10-27
BRPI1013854A2 (pt) 2017-05-16
JP2012524769A (ja) 2012-10-18

Similar Documents

Publication Publication Date Title
PE20220430A1 (es) PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
ECSP099078A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
CU24053B1 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
CO6251282A2 (es) Oxazolidinonas sustituidas y su uso
UY32730A (es) Inhibidores de cyp17
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
PA8759501A1 (es) Formas cristalinas
AR063923A1 (es) Sales del acido zoledronico, procesos de preparacion y composiciones
UY32877A (es) Inhibidores heteroarílicos de cinasa.
PE20140966A1 (es) Quinazolincarboxamida azetidinas
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CR11859A (es) Composición y proceso-356
BR112013017977A2 (pt) formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia
AR053345A1 (es) Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa
AR076407A1 (es) Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal